SITE MAP   |   CONTACT US


2009 Annual Report on Form 10-K 2009
2008 Annual Report on Form 20-F 2008
2007 Annual Report on Form 20-F 2007
2006 Annual Report 2006
2005 Annual Report 2005
2004 Annual Report 2004
2003 Annual Report 2003
2002 Annual Report 2002
2001 Annual Report 2001
2000 Annual Report 2000
1999 Annual Report 1999
2010 2nd Quarter Interim Report 2010
2010 1st Quarter Interim Report 2010
2010 Management Proxy Circular 2010
2009 3rd Quarter Interim Report 2009
2009 2nd Quarter Interim Report 2009
2009 1st Quarter Interim Report 2009
2008 Management Proxy Cirular 2008
2008 3rd Quarter Interim Report 2008
2008 2nd Quarter Interim Report 2008
2008 1st Quarter Interim Report 2008
2007 Financial Results 2008
2007 Management Proxy Cirular 2007
2007 3rd Quarter Interim Report 2007
2007 2nd Quarter Interim Report 2007
2007 1st Quarter Interim Report 2007
2006 3rd Quarter Interim Report 2006
2006 2nd Quarter Interim Report 2006
2006 1st Quarter Interim Report 2006
2005 3rd Quarter Interim Report 2005
2005 2nd Quarter Interim Report For Canadian Regulatory Purposes 2005
2005 2nd Quarter Interim Report 2005
2005 1st Quarter Interim Report 2005
2004 3rd Quarter Interim Report 2004
2004 2nd Quarter Interim Report 2004
2004 1st Quarter Interim Report 2004
2003 3rd Quarter Interim Report 2003
2003 2nd Quarter Interim Report 2003
2003 1st Quarter Interim Report 2003
2002 3rd Quarter Interim Report 2002
2002 2nd Quarter Interim Report 2002
2002 1st Quarter Interim Report 2002
2001 3rd Quarter Interim Report 2001
2001 2nd Quarter Interim Report 2001
2001 1st Quarter Interim Report 2001
6.75% Convertible Subordinated Preferred Equivalent Debentures Due March 31, 2025 2000
2000 3nd Quarter Interim Report 2000
2000 2nd Quarter Interim Report 2000
2000 1st Quarter Interim Report 2000
Proxy for Common Shares 1999
Notice of Special Shareholders Meeting 1999
Dissent Rights 1999
1999 Proxy Statement 1999
1999 Meeting 1999
1999 Circular 1999
1999 3rd Quarter Interim Report 1999
1999 2nd Quarter Interim Report 1999
1999 1st Quarter Interim Report 1999

Tools

Investment Calculator


Email Alerts

Resources

Q2 2010 Financial Results

Valeant - Biovail Analyst Investor Presentation

Biovail - Valeant Merger Conference Call

Biovail's Product Pipeline

Pimavanserin Schizophrenia Co-Therapy - Phase 2 Data

Aplenzin Prescribing Information

Nitoman Prescribing Information

Xenazine Prescribing Information

Xenazine Medication Guide

Corporate Fact Sheet

IMPORTANT: Income Tax Information for Canadian Resident Shareholders


Download Adobe Acrobat Reader

Events


© 2007 Biovail Corporation - All Rights Reserved (BIO113B0602) Privacy Policy   |   Disclaimers